Migraine Model Development Services
Ace Therapeutics provides tailored preclinical contract research organization services dedicated to supporting analgesic drug development. We specialize in the establishment and application of reliable in vivo migraine models to evaluate candidate compounds through comprehensive endpoint assessments. Our services are designed to assist pharmaceutical and biotech partners in identifying and optimizing therapeutic agents for migraine-related pain, focusing on data-driven decisions supported by pharmacological, behavioral, histological, molecular, and electrophysiological evaluations.
Migraine is a prevalent and disabling neurological condition characterized by recurring moderate to severe headaches, often accompanied by nausea, photophobia, and phonophobia. Unlike acute pain models, migraine involves both peripheral and central sensitization mechanisms, with key roles played by trigeminovascular activation, neuroinflammation, and cortical spreading depression (CSD). These complexities necessitate specialized in vivo models that can faithfully mimic human migraine pathophysiology and provide a platform for screening and evaluating novel therapeutic agents.
We utilize multiple validated rodent models that replicate specific pathophysiological mechanisms of migraine.
| Model Type | Induction Method | Key Applications |
| Nitroglycerin-Induced Migraine Model | Systemic nitroglycerin injection | Episodic migraine, peripheral sensitization |
| Cortical Spreading Depression (CSD) | Potassium chloride or optogenetics-triggered CSD | Aura-related migraine, central sensitization |
| Inflammatory Soup (IS) Model | Dural infusion of inflammatory mediators | Trigeminal activation, neuroinflammation |
| CGRP-Induced Migraine Model | Intravenous/intrathecal CGRP administration | CGRP-targeting drug evaluation |
| Reserpine Model | Chronic administration inducing migraine-like attacks | Chronic migraine screening |
These models are supported by behavioral assessments and mechanistic endpoints that reflect migraine pathology in humans.
We emphasize comprehensive in vivo evaluations that capture both symptom relief and mechanistic insights.
Behavioral Assessments
Biomarker and Molecular Analyses
Histology and Imaging
Electrophysiology and CSD Monitoring
PK/PD and Safety Studies
Our migraine model services are suitable for evaluating a wide range of therapeutic modalities, including:
Ace Therapeutics is committed to enabling the discovery and development of next-generation migraine therapeutics. Whether your compound targets central sensitization, neuropeptides, or inflammatory cascades, our integrated migraine model services provide the in vivo data necessary to advance confidently to the next stage of development.
What's the best model for testing triptans or gepants?
The nitroglycerin model is highly predictive for compounds acting via serotonergic or CGRP receptor pathways.
Can your team perform EEG or electrophysiological readouts?
Yes, we offer cortical spreading depression monitoring and neural firing analysis depending on the model.
Are your models suitable for chronic migraine drug candidates?
Yes, we provide chronic sensitization models like the reserpine model to support long-term efficacy studies.
How do you measure behavioral changes in migraine models?
We use validated assays such as grimace scales, tactile allodynia (von Frey), and photophobia tests under controlled conditions.
Can you assist in biomarker discovery related to migraine?
Yes, we support multiplex cytokine analysis, CGRP quantification, and immunohistochemical tissue profiling.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics comprises a team of highly committed and skilled researchers focused exclusively on providing innovative preclinical contract research solutions for novel analgesic development. We deliver rigorous models and data essential for advancing targeted, non-addictive pain therapies toward clinical evaluation.